Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 199

1.

Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.

De Laurentiis M, Bonfadini C, Lorusso V, Cilenti G, Di Rella F, Altavilla G, Otero M, Ardizzoia A, Marchetti P, Peverelli G, Amoroso D, Vecchio S, Fiorio E, Orecchia S.

Support Care Cancer. 2018 Dec;26(12):4021-4029. doi: 10.1007/s00520-018-4259-1. Epub 2018 Jun 25.

PMID:
29943152
2.

miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model.

Callegari E, D'Abundo L, Guerriero P, Simioni C, Elamin BK, Russo M, Cani A, Bassi C, Zagatti B, Giacomelli L, Blandamura S, Moshiri F, Ultimo S, Frassoldati A, Altavilla G, Gramantieri L, Neri LM, Sabbioni S, Negrini M.

Mol Ther Nucleic Acids. 2018 Jun 1;11:485-493. doi: 10.1016/j.omtn.2018.04.002. Epub 2018 Apr 12.

3.

Liquid biopsy for lung cancer early detection.

Santarpia M, Liguori A, D'Aveni A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, Lazzari C, Altavilla G, Rosell R.

J Thorac Dis. 2018 Apr;10(Suppl 7):S882-S897. doi: 10.21037/jtd.2018.03.81. Review.

4.

Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy.

Lucchesi S, Marcianò I, Panagia P, Intelisano R, Randazzo MP, Sgroi C, Altavilla G, Santarpia M, Adamo V, Franchina T, Ferraù F, Reitano P, Trifirò G.

Clin Drug Investig. 2018 Mar;38(3):279-285. doi: 10.1007/s40261-017-0613-1.

5.

Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy.

Lucchesi S, Marcianò I, Panagia P, Intelisano R, Randazzo MP, Sgroi C, Altavilla G, Santarpia M, Adamo V, Franchina T, Ferraù F, Reitano P, Trifirò G.

Clin Drug Investig. 2018 Mar;38(3):269-278. doi: 10.1007/s40261-017-0591-3. Erratum in: Clin Drug Investig. 2017 Dec 30;:.

6.

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.

Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R.

Lung Cancer (Auckl). 2017 Aug 18;8:109-125. doi: 10.2147/LCTT.S119644. eCollection 2017. Review.

7.

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.

Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G.

Drug Des Devel Ther. 2017 Jul 5;11:2047-2063. doi: 10.2147/DDDT.S113500. eCollection 2017. Review.

8.

Nail toxicities induced by liposomal doxorubicin: a retrospective case series.

Vaccaro M, Santarpia M, Borgia F, Giuffrida R, Altavilla G, Piraccini BM, Cannavò SP.

Eur J Dermatol. 2017 Aug 1;27(4):434-435. doi: 10.1684/ejd.2017.3047. No abstract available.

PMID:
28508752
9.

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

Lazzari C, Karachaliou N, Gregorc V, Bulotta A, Gonzalez-Cao M, Verlicchi A, Altavilla G, Rosell R, Santarpia M.

Expert Rev Respir Med. 2017 Jun;11(6):469-479. doi: 10.1080/17476348.2017.1326822. Epub 2017 May 15. Review.

PMID:
28467720
10.

Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.

Karachaliou N, Santarpia M, Gonzalez Cao M, Teixido C, Sosa AE, Berenguer J, Rodriguez Capote A, Altavilla G, Rosell R.

Expert Opin Investig Drugs. 2017 Jun;26(6):713-722. doi: 10.1080/13543784.2017.1324572. Epub 2017 May 18. Review.

PMID:
28463570
11.

HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology.

Cafaro A, Piccaro G, Altavilla G, Gigantino V, Matarese G, Olivieri E, Ferrantelli F, Ensoli B, Palma C.

BMC Infect Dis. 2016 Aug 22;16(1):442. doi: 10.1186/s12879-016-1724-7.

12.

Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications.

Di Paolo A, Del Re M, Petrini I, Altavilla G, Danesi R.

Epigenomics. 2016 Aug;8(8):1151-67. doi: 10.2217/epi.16.10. Epub 2016 Aug 1. Review.

PMID:
27479016
13.

Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments?

Mondello P, Mian M, Pitini V, Cuzzocrea S, Sindoni A, Galletti M, Mandolfino M, Santoro D, Mondello S, Aloisi C, Altavilla G, Benvenga S.

Curr Oncol. 2016 Jun;23(3):e165-70. doi: 10.3747/co.23.3026. Epub 2016 Jun 9.

14.

Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single-institution, retrospective case series.

Vaccaro M, Santarpia M, Calapai G, Mannucci C, Borgia F, Altavilla G, Cannavò SP.

Br J Dermatol. 2017 Feb;176(2):507-509. doi: 10.1111/bjd.14806. Epub 2016 Dec 27. No abstract available.

PMID:
27291307
15.

Recent developments in the use of immunotherapy in non-small cell lung cancer.

Santarpia M, Giovannetti E, Rolfo C, Karachaliou N, González-Cao M, Altavilla G, Rosell R.

Expert Rev Respir Med. 2016 Jul;10(7):781-98. doi: 10.1080/17476348.2016.1182866. Epub 2016 May 13. Review.

PMID:
27148808
16.

Feasibility of cell-free circulating tumor DNA testing for lung cancer.

Santarpia M, Karachaliou N, González-Cao M, Altavilla G, Giovannetti E, Rosell R.

Biomark Med. 2016;10(4):417-30. doi: 10.2217/bmm.16.6. Epub 2016 Mar 14. Review.

PMID:
26974841
17.

Targeted drugs in small-cell lung cancer.

Santarpia M, Daffinà MG, Karachaliou N, González-Cao M, Lazzari C, Altavilla G, Rosell R.

Transl Lung Cancer Res. 2016 Feb;5(1):51-70. doi: 10.3978/j.issn.2218-6751.2016.01.12. Review.

18.

Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.

Santarpia M, González-Cao M, Viteri S, Karachaliou N, Altavilla G, Rosell R.

Transl Lung Cancer Res. 2015 Dec;4(6):728-42. doi: 10.3978/j.issn.2218-6751.2015.12.04. Review.

19.

Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.

Vaccaro M, Guarneri F, Borgia F, Pollicino A, Altavilla G, Cannavò SP.

J Dermatolog Treat. 2016;27(2):148-52. doi: 10.3109/09546634.2015.1086478. Epub 2015 Sep 24.

PMID:
26313697
20.

Efficacy of clindamycin phosphate and benzoyl peroxide gel (DUAC(®) ) in the treatment of EGFR inhibitors-associated acneiform eruption.

Vaccaro M, Guarneri F, Borgia F, Pollicino A, Altavilla G, Cannavò SP.

J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1436-8. doi: 10.1111/jdv.13278. Epub 2015 Aug 20. No abstract available.

PMID:
26290481

Supplemental Content

Loading ...
Support Center